7034
J. S. Clark, M. D. Middleton / Tetrahedron Letters 44 (2003) 7031–7034
perform these operations in a one-pot fashion without
isolation of the intermediate azalactones 12.
Altorfer, M.; Lehmann, C.; Scho¨nholzer, P.; Mu¨ller, K. J.
Org. Chem. 1996, 61, 4080; (d) Yokum, T. S.; Gauthier, T.
J.; Hammer, R. P.; McLaughlin, M. L. J. Am. Chem. Soc.
1997, 119, 1167.
Now that we have addressed reactivity issues, the final
task is to perform ylide formation and rearrangement
in an enantioselective fashion. Studies toward this goal
are currently in progress and results of this work will be
reported in due course.
3. (a) Mori, T.; Takahashi, K.; Kashiwabara, M.; Uemara,
D. Tetrahedron Lett. 1985, 26, 1073; (b) Kluepfel, D.;
Bagli, J.; Baker, H.; Charest, M. P.; Kudelski, A. J.
Antibiot. 1972, 25, 109.
4. Berkowitz, D. B.; Jahng, W.-J.; Pederson, M. L. Bioorg.
Med. Chem. Lett. 1996, 6, 2151.
Acknowledgements
5. (a) Curry, K.; Peet, M. J.; Magnuson, D. S. K.; McLen-
nan, H. J. Med. Chem. 1988, 31, 864; (b) Monn, J. A.;
Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.;
Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.;
Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.;
Tomlinson, R.; Lewis, R.; Griffey, K. R.; Tizzano, J. P.;
Schoepp, D. D. J. Med. Chem. 1999, 42, 1027; (c) Bradley,
D. M.; Mapitse, R.; Thomson, N. M.; Hayes, C. J. J. Org.
Chem. 2002, 67, 7613.
We thank the University of Nottingham for the award
of a studentship to M.D.M. and Aventis Pharmaceuti-
cals, Bridgewater, New Jersey for financial support. We
also thank Dr. Paul Cox (Aventis Pharmaceuticals,
Bridgewater, New Jersey) for his interest in this work.
6. Clark, J. S.; Middleton, M. D. Org. Lett. 2002, 4, 765.
7. (a) Kovacs, J.; Mayers, G. L.; Johnson, R. H.; Cover, R.
E.; Ghatak, U. R. Chem. Commun. 1970, 53; (b) Kovacs,
J.; Mayers, G. L.; Johnson, R. H.; Cover, R. E.; Ghatak,
U. R. J. Org. Chem. 1970, 35, 1810; (c) Kisfaludy, L.;
Roberts, J. E.; Johnson, R. H.; Mayers, G. L.; Kovacs, J.
J. Org. Chem. 1970, 35, 3563.
References
1. (a) Gante, J. Angew. Chem., Int. Ed. Engl. 1994, 33, 1699;
(b) Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bo¨s, M.;
Cook, C. M.; Fry, D. C.; Graves, B. J.; Hatada, M.; Hill,
D. E.; Kahn, M.; Madison, V. S.; Rusiecki, V. K.; Sarabu,
R.; Sepinwall, J.; Vincent, G. P.; Voss, M. E. J. Med.
Chem. 1993, 36, 3039.
2. (a) Altmann, K.-H.; Altmann, E.; Mutter, M. Helv. Chim.
Acta 1992, 75, 1198; (b) Aubry, A.; Bayeul, D.; Pre´cigoux,
G.; Pantano, M.; Formaggio, F.; Crisma, M.; Toniolo, C.;
Boesten, W. H. J.; Schoemaker, H. E.; Kamphuis, J. J.
Chem. Soc., Perkin Trans. 2 1994, 525; (c) Obrecht, D.;
8. The substituted salicaldehydes 9a and 9b are readily avail-
able: 2-hydroxy-5-fluorobenzaldehyde (9a) was prepared
from
2-bromo-4-fluorophenol
by
lithium–halogen
exchange and reaction with dimethylformamide, and 2-
hydroxy-5-nitrobenzaldehyde (9b) is commercially avail-
able.